Paxlovid outperforms molnupiravir against severe COVID-19 outcomes --study

New data show Paxlovid outperforms molnupiravir against severe COVID-19 outcomes A large study yesterday in the International Journal of Infectious Diseases shows that, if prescribed within 5 days of confirmed infection, Paxlovid (nirmatrelvir-ritonavir) is more effective in protecting against all-cause mortality and severe COVID-19 in adults than is molnupiravir, another antiviral drug. CIDRAP

...

The study was conducted in Hong Kong in 2022. Researchers said they also found no significant difference between CoronaVac (made by Sinovac Biotech) and Comirnaty (Pfizer-BioNTech) vaccines in the effectiveness of reducing all-cause mortality and progression to severe COVID-19.

...